KVUE Stock Analysis: Kenvue | NYSE
Household & Personal Products | NYSE, USA | Market Cap: 33.037m USD | 12M Return: 14.6% | US49177J1025 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 397M
EPS Trend: -56.9%
Qual. Beats: 0
Rev. Trend: -64.6%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 3.4 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Kenvue Inc. (NYSE: KVUE) is a global consumer health company headquartered in Summit, New Jersey, formed through a 2023 spin-off from Johnson & Johnson. It operates across three segments-Self Care, Skin Health and Beauty, and Essential Health-selling over-the-counter medicines, personal care items, oral and baby care products, and vitamins/supplements in markets spanning North America, Europe, the Middle East, Africa, Asia-Pacific, and Latin America. Its brand portfolio includes household names such as Tylenol, Band-Aid, Neutrogena, Johnsons, Listerine, Benadryl, Zyrtec, Aveeno, and Rogaine. Within the Consumer Staples sector, Kenvue benefits from the defensive characteristics typical of personal care and OTC healthcare products, including stable, recurring demand driven by brand loyalty and essential everyday use.
- Skin Health and Beauty segment posts declining sales amid competition
- Tylenol faces escalating litigation over autism pregnancy claims
- Starboard activist pushes board for cost cuts and restructuring
| Net Income: 1.66b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.08 > 0.02 and ΔFCF/TA 1.90 > 1.0 |
| NWC/Revenue: 0.21% < 20% (prev -0.89%; Δ 1.09% < -1%) |
| CFO/TA 0.09 > 3% & CFO 2.33b > Net Income 1.66b |
| Net Debt (7.50b) to EBITDA (3.17b): 2.37 < 3 |
| Current Ratio: 1.01 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.92b) vs 12m ago -0.21% < -2% |
| Gross Margin: 58.19% > 18% (prev 57.99%; Δ 0.20% > 0.5%) |
| Asset Turnover: 57.21% > 50% (prev 55.80%; Δ 1.40% > 0%) |
| Interest Coverage Ratio: 6.91 > 6 (EBIT TTM 2.60b / Interest Expense TTM 376.0m) |
| A: 0.00 (Total Current Assets 5.90b - Total Current Liabilities 5.87b) / Total Assets 26.7b |
| B: -0.00 (Retained Earnings -70.0m / Total Assets 26.7b) |
| C: 0.10 (EBIT TTM 2.60b / Avg Total Assets 26.9b) |
| D: 0.65 (Book Value of Equity 10.6b / Total Liabilities 16.2b) |
| Altman-Z'' = 1.33 = BB |
| DSRI: 1.01 (Receivables 2.93b/2.86b, Revenue 15.4b/15.1b) |
| GMI: 1.00 (GM 57.99% / 58.19%) |
| AQI: 0.98 (AQ_t 0.70 / AQ_t-1 0.71) |
| SGI: 1.02 (Revenue 15.4b / 15.1b) |
| TATA: -0.02 (NI 1.66b - CFO 2.33b) / TA 26.7b) |
| Beneish M = -3.02 (Cap -4..+1) = AA |
As of October 08, 2026, the stock is trading at USD 17.53 with a total of 11,878,502 shares traded. Over the past week, the price has changed by -0.74%, over one month by -3.54%, over three months by -9.32% and over the past year by +14.62%.
Current recommended Stop Loss: 16.80 (which is 4.2% or 2.3 ATR below the current price).
Kenvue has received a consensus analysts rating of 3.21. Therefore, it is recommended to hold KVUE.
- StrongBuy: 1
- Buy: 1
- Hold: 12
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 19.5 | 11.2% |
P/E Trailing = 20.2353
P/E Forward = 14.7275
P/S = 2.1442
P/B = 3.2162
P/EG = 1.4024
Revenue TTM = 15.4b USD
EBIT TTM = 2.60b USD
EBITDA TTM = 3.17b USD
Long Term Debt = 7.07b USD (from longTermDebt, last quarter)
Short Term Debt = 1.41b USD (from shortTermDebt, last quarter)
Debt = 8.61b USD (from shortLongTermDebtTotal, last quarter) + Leases 133.0m
Net Debt = 7.50b USD (calculated: Debt 8.61b - CCE 1.11b)
Enterprise Value = 40.5b USD (33.0b + Debt 8.61b - CCE 1.11b)
Interest Coverage Ratio = 6.91 (Ebit TTM 2.60b / Interest Expense TTM 376.0m)
EV/FCF = 19.15x (Enterprise Value 40.5b / FCF TTM 2.12b)
FCF Yield = 5.22% (FCF TTM 2.12b / Enterprise Value 40.5b)
FCF Margin = 13.74% (FCF TTM 2.12b / Revenue TTM 15.4b)
Net Margin = 10.76% (Net Income TTM 1.66b / Revenue TTM 15.4b)
Gross Margin = 58.19% ((Revenue TTM 15.4b - Cost of Revenue TTM 6.44b) / Revenue TTM)
Gross Margin QoQ = 58.18% (prev 58.89%)
Tobins Q-Ratio = 1.52 (Enterprise Value 40.5b / Total Assets 26.7b)
Interest Expense / Debt = 4.37% (Interest Expense 376.0m / Debt 8.61b)
Taxrate = 25.42% (565.0m / 2.22b)
NOPAT = 1.94b (EBIT 2.60b * (1 - 25.42%))
Current Ratio = 1.01 (Total Current Assets 5.90b / Total Current Liabilities 5.87b)
Debt / Equity = 0.82 (Debt 8.61b / totalStockholderEquity, last quarter 10.6b)
Debt / EBITDA = 2.37 (Net Debt 7.50b / EBITDA 3.17b)
Debt / FCF = 3.54 (Net Debt 7.50b / FCF TTM 2.12b)
Total Stockholder Equity = 10.6b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.16% (Net Income 1.66b / Total Assets 26.7b)
RoE = 15.58% (Net Income TTM 1.66b / Total Stockholder Equity 10.6b)
RoCE = 14.67% (EBIT 2.60b / Capital Employed (Equity 10.6b + L.T.Debt 7.07b))
RoIC = 9.01% (NOPAT 1.94b / Invested Capital 21.5b)
WACC = 4.92% (E(33.0b)/V(41.7b) * Re(5.35%) + D(8.61b)/V(41.7b) * Rd(4.37%) * (1-Tc(0.25)))
Discount Rate = 5.35% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 3.00 | Cagr: 0.07%
[DCF] Terminal Value 77.97% ; FCFF base≈1.92b ; Y1≈2.20b ; Y5≈3.24b
[DCF] Fair Price = 21.52 (EV 48.8b - Net Debt 7.50b = Equity 41.3b / Shares 1.92b; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -56.90 | EPS CAGR: -7.84% | SUE: -0.45 | # QB: 0
Revenue Correlation: -64.60 | Revenue CAGR: -0.80% | SUE: -0.20 | # QB: 0
EPS current Quarter (2026-09-30): EPS=0.29 | Chg30d=+0.00% | Revisions=-44% | Analysts=9
EPS current Year (2026-12-31): EPS=1.18 | Chg30d=+0.30% | Revisions=-50% | GrowthEPS=+9.5% | GrowthRev=+3.1%
EPS next Year (2027-12-31): EPS=1.24 | Chg30d=+0.32% | Revisions=+17% | GrowthEPS=+4.9% | GrowthRev=+2.4%
[Analyst] Revisions Ratio: -43% (up=5, down=15)